Voronezh State Medical University named after N. N. Burdenko, Voronezh, The Russian Federation
*Corresponding author: Evgeniy S. Ovsyannikov, PhD. Department of faculty therapy, Voronezh State Medical University named after N.N. Burdenko. Voronezh, Russia. E-mail: email@example.com.
Published: June 16, 2017. doi: 10.21103/Article7(2)_OA3
Background: The improvement of asthma treatment is still one of the urgent issues of modern medicine. The objective of this study was to evaluate the dynamics of lipid peroxidation parameters in patients with asthma receiving complex therapy with ceruloplasmin (Cp).
Methods and Results: The study included 92 patients with severe uncontrolled asthma. Patients were divided into 2 groups. The case group consisted of 45 patients, whose treatment was conventional therapy combined with Cp produced by “MICROGEN” (Russia). Cp 100 mg was administered intravenously once daily for 7 days. The control group consisted of 47 patients who received conventional treatment: inhaled and systemic corticosteroids, bronchodilators, and, if necessary, antibiotics and oxygen therapy. All participants underwent a comprehensive examination, including clinical investigation, chest radiography, assessment of spirometry parameters (VC, FVC, FEV1, FEV1/FVC ratio, PEFR, FEF 25-75), and determination of MDA, metHB, HbCO, total sulfhydryl groups, and SOD activity in blood plasma. Patients of the case group showed a statistically significant decrease in elevated rates of MDA and HbCO, an increase in SOD activity and the content of sulfhydryl groups.
Conclusion: Cp in complex treatment of patients with asthma allows eliminating the imbalance in the prooxidant-antioxidant system and providing an obviously positive clinical effect.
1. Global Initiative for Asthma. The Global Strategy for Asthma Management and Prevention, 2017. Available from: http://www.ginasthma.org/.
2. Global surveillance, prevention and control of chronic respiratory diseases: A comprehensive approach. WHO 2007. Available from: http://www.who.int/respiratory/publications/global_surveillance/en/
3. Provotorov VM, Budnevsky AV, Filatova YI. [Clinical manifestations of asthma during combination therapy using ceruloplasmin]. Ter Arkh. 2016;88(3):36-9. [Article in Russian].
4. Provotorov VM, Budnevsky AV, Filatova YI, Perfil'eva MV. [Antioxidant therapy of bronchial asthma]. Klin Med (Mosk). 2015;93(8):19-22. [Article in Russian].
5. Ermolova AV, Budnevsky AV, Yu ME, Ovsyannikov ES, Drobysheva ES. [Bronchial asthma and metabolic syndrome]. Klin Med (Mosk). 2015;93(6):44-9. [Article in Russian].
6. Sahiner UM, Birben E, Erzurum S, Sackesen C, Kalayci O. Oxidative stress in asthma. World Allergy Organ J. 2011;4(10):151-8. doi: 10.1097/WOX.0b013e318232389e.
7. Latysheva AN, Smirnova SV, Kolpakova AF. Bronchial asthma and chronic obstructive pulmonary disease: characteristics of oxidant-antioxidant state. Krasnojarsk: KraGMU; 2011.
8. Kirkham P, Rahman I. Oxidative stress in asthma and COPD: antioxidants as a therapeutic strategy. Pharmacol Ther. 2006;111(2):476-94.
9. Soodaeva SK. [Free radical mechanisms of injury in respiratory disease. Russian Pulmonology]. 2012;(1):5-10.[Article in Russian].
10. Lushchak VI. Oxidative stress and mechanisms of protection against it in bacteria. Biochemistry (Mosc). 2001;66(5):476-89.
11. Karmen NB, Abdullaeva MA, Tokareva LV. [Electropulse therapy in the treatment of severe bronchial asthma]. MEDLINE.RU (Pul'monologiia) 2011;12:679-689. [Article in Russian].
12. Soodaeva SK, Klimanov IA. [Disorders of oxidative metabolism in diseases of the respiratory tract and modern approaches to antioxidant therapy]. Atmosfere. Pul'monologiia i allergologiia (M0sk). 2009;(1):34-8.[Article in Russian]/
13. National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. J Allergy Clin Immunol. 2007;120(5 Suppl):S94–138.
14. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008;31(1):143–78. doi: 10.1183/09031936.00138707.
15. Majori M, Vachier I, Godard P, Farce M, Bousquet J, Chanez P. Superoxide anion production by monocytes of corticosteroid-treated asthmatic patients. Eur Respir J. 1998;11(1):133–8.
16. De Raeve HR, Thunnissen FB, Kaneko FT, Guo FH, Lewis M, Kavuru MS,et al. Decreased Cu, Zn-SOD activity in asthmatic airway epithelium: correction by inhaled corticosteroid in vivo. Am J Physiol. 1997;272(1 Pt 1): L148–54.
17. Fenech AG, Ellul-Micallef R. Selenium glutathione peroxidase and superoxide dismutase in maltese asthmatic patients: effect of glucocorticoid administration. Pulm Pharmacol Ther. 1998;11(4):301–8.
18. Sartorelli CF, Rehder J, Neto AC, Vilela MM. Assessment of inflammation based on the release of oxygen radicals by granulocytes in chronic uncontrolled asthma. J Pediatr. (Rio J) 2009;85(2):143-8. doi:10.2223/JPED.1881.
19. Farhutdinov UR, Farhutdinov ShU. [Efficacy of ceruloplasmin in patients with asthma]. Ter Arh. 2012;84(12):45-8. [Article in Russian].
20. Giurgea N, Constantinescu MI, Stanciu R, Suciu S, Muresan A. Ceruloplasmin - acute-phase reactant or endogenous antioxidant? The case of cardiovascular disease. Med Sci Monit. 2005;11(2):RA48-51.
21. Moshkov KA, Zaitsev VN, Romanovskaya EV, Stefanov VE. Ceruloplasmin: intramolecular transfer and ferroxidase activity. Fundamental Research (Mosk). 2014;3(Part 1):104–8.
22. Al-Khalaf MI, Kholoud S Ramadan KS. Oxidants and Antioxidants Status in Bronchial Asthma. Asian Journal of Applied Sciences. 2013;1(4):123-33.
23. Jiang L, Diaz PT, Best TM, Stimpfl JN, He F, Zuo L. Molecular characterization of redox mechanisms in allergic asthma. Ann Allergy Asthma Immunol. 2014;113(2):137-42. doi: 10.1016/j.anai.2014.05.030.
24. Birben E, Sahiner UM, Sackesen C, Erzurum S, Kalayci O. Oxidative stress and antioxidant defense. World Allergy Organ J. 2012;5(1):9-19. doi: 10.1097/WOX.0b013e3182439613.
25. Demko IV, Sobko EA, Chubarova SV, Soloveva IA, Kraposhina AYu, Medvedeva NN, et al. [Features of the systemic inflammation, external respiration functions and morphological structure of the bronchial mucous membrane in severe bronchial asthma.]Siberian Medical Review (Krasnoyarsk). 2014;(5):47-52. [Article in Russian]
26. Raju KR, Kumar MN, Gupta S, Naga ST, Shankar JK, Murthy V, et al. 5-Aminosalicylic acid attenuates allergen-induced airway inflammation and oxidative stress in asthma. Pulm Pharmacol Ther. 2014;29(2):209-16. doi: 10.1016/j.pupt.2014.07.007.
27. Al-Harbi NO, Nadeem A, Al-Harbi MM, Imam F, Al-Shabanah OA, Ahmad SF, et al. Oxidative airway inflammation leads to systemic and vascular oxidative stress in a murine model of allergic asthma. Int Immunopharmacol. 2015;26(1):237-45. doi: 10.1016/j.intimp.2015.03.032.
28. Kang JH1, Kim KS, Choi SY, Kwon HY, Won MH. Oxidative modification of human ceruloplasmin by peroxyl radicals. Biochem Biophys Acta. 2001; 1568(1):30–6.
29. Goldstein IM, Kaplan HB, Edelson HS, Weissmann G. Ceruloplasmin. A scavenger of superoxide anion radicals. J Biol Chem. 1979; 254(10): 4040–5
30. Gutteridge JM. Inhibition of the Fenton reaction by the protein ceruloplasmin and other copper complexes. Assessment of feroxidase and radical scavenging activities. Chem Biol Interact. 1985;56(1):113–20.
31. Lazutkina EL, Muzychenko LM, Landyshev JuS, Tsyrendorzhiev DD, Lazarenko LL. Peculiarities of pro- and antioxidant status of blood serum in bronchial asthma patients with varied sensitization. Bulletin Physiology and Pathology of Respiration (Blagoveshchensk). 2014;51:15-19. [Article in Russian].
The fully formatted PDF version is available.
International Journal of Biomedicine. 2017;7(2):104-107. © 2017 International Medical Research and Development Corporation. All rights reserved.